Psychedelic-assisted psychotherapy and its potential to manage demoralization: A brief exploration of an alternative approach to end of life care
May 7, 2025 DOI: 10.70462/acim.2025.1.001 via OpenAlex
Summary
AI-generated from the abstractAustralia has become the first country to approve MDMA and psilocybin for clinical treatment of post-traumatic stress disorder and treatment-resistant depression. This article explores the history of psychedelic use, how these substances work, and the hope they may offer people receiving end-of-life care.
Study at a glance
| Characteristics | Review |
|---|---|
| Keywords | Psychotherapist Psychology End-of-life care Medicine |
| Key finding | Australia is the first country to approve MDMA and psilocybin for clinical treatment of PTSD and treatment-resistant depression. |
Abstract
Australia has become the first country to approve the use of psychedelics, namely MDMA and psilocybin, for clinical treatment of post-traumatic stress disorder and treatment-resistant depression. Here, we briefly explore the history of its use, how it works, and the hope it may provide people receiving end-of-life care.